Curative Biotechnology Inc (CUBT) - Total Assets
Based on the latest financial reports, Curative Biotechnology Inc (CUBT) holds total assets worth $2.07 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Curative Biotechnology Inc - Total Assets Trend (2013–2025)
This chart illustrates how Curative Biotechnology Inc's total assets have evolved over time, based on quarterly financial data. Also see CUBT stock market capitalisation for the company's overall valuation and market capitalisation.
Curative Biotechnology Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Curative Biotechnology Inc's total assets of $2.07 Million consist of 5.2% current assets and 94.8% non-current assets. Review Curative Biotechnology Inc (CUBT) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 2.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.31 Million | 62.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Curative Biotechnology Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Curative Biotechnology Inc share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Curative Biotechnology Inc's current assets represent 5.2% of total assets in 2025, a decrease from 50.5% in 2013.
- Cash Position: Cash and equivalents constituted 2.1% of total assets in 2025, up from 1.6% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 61.0% of total assets, an increase from 29.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 62.0% of total assets.
Curative Biotechnology Inc Competitors by Total Assets
Key competitors of Curative Biotechnology Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Vaxcyte Inc
NASDAQ:PCVX
|
USA | $3.14 Billion |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $1.11 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.16 Billion |
Curative Biotechnology Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.01 | 0.05 | 3.63 |
| Quick Ratio | 0.01 | 0.05 | 3.63 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-8.27 Million | $-6.92 Million | $548.14K |
Curative Biotechnology Inc - Advanced Valuation Insights
This section examines the relationship between Curative Biotechnology Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 3.09 |
| Asset Growth Rate (YoY) | -2.5% |
| Total Assets | $2.11 Million |
| Market Capitalization | $6.51 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Curative Biotechnology Inc's assets at a significant premium (3.09x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Curative Biotechnology Inc's assets decreased by 2.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Curative Biotechnology Inc (2013–2025)
The table below shows the annual total assets of Curative Biotechnology Inc from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $2.11 Million | -2.51% |
| 2024-12-31 | $2.16 Million | -16.89% |
| 2023-12-31 | $2.60 Million | +24.60% |
| 2022-12-31 | $2.09 Million | -13.39% |
| 2021-12-31 | $2.41 Million | +6.07% |
| 2020-12-31 | $2.27 Million | +5617.42% |
| 2019-12-31 | $39.77K | -11.76% |
| 2018-12-31 | $45.08K | -23.55% |
| 2017-12-31 | $58.96K | -10.55% |
| 2016-12-31 | $65.91K | -3.32% |
| 2015-12-31 | $68.17K | -63.58% |
| 2014-12-31 | $187.19K | -18.03% |
| 2013-12-31 | $228.38K | -- |
About Curative Biotechnology Inc
Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying… Read more